Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2003

View Archived Issues

Low plasma IL-10 levels associated with neurological deterioration in acute ischemic stroke patients

Orally available prodrugs of anxiolytic mGluR agonists described by Lilly

Lilly presents novel 5-HT receptor modulators for use in depression and anxiety

Novel inhibitors of microglial activation with utility in stroke

Novartis discloses novel IOP-lowering agents

AI-700 enters phase III clinical testing

Serono seeks European approval for Raptiva for psoriasis

Praecis resubmits Plenaxis NDA

Pet-1 identified as the gene responsible for normal levels of anxiety and aggression in mice

HHS announces contracts to develop MVA-based smallpox vaccines

New DHODH inhibitors and their use described by 4SC researchers

Recent patent covers new PPAR agonists discovered at Dr. Reddy's Laboratories

Nikken Chemicals claims a selective PDE4 inhibitor with utility in asthma, dermatitis, etc.

Novel Src kinase inhibitors prepared and tested at Aventis

NeoRx submits phase II dosimetry results for skeletal targeted radiotherapy

NPS updates progress of Preos and cinacalcet

FDA approval for Gliadel Wafer during initial surgery for primary malignant glioma

Results of AVI-4126 in PKD patients

Risperdal Consta approved in Spain

Lexicon Genetics identifies novel target for development of osteoporosis drugs

PNA technology discovered at Mayo Clinic covered by U.S. patent

Affinium acquires antibacterial program from GlaxoSmithKline

Inflazyme makes strides in Q3

Neurogen summarizes pipeline progress

Xerion advances therapeutic antibody pipeline

Broad-spectrum antithrombotic properties described for SSR-182289A

Chymase inhibitor prevents intimal hyperplasia after ballon injury

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...